Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.04
-1.66 (-5.24%)
At close: Oct 31, 2025, 4:00 PM EDT
29.45
-0.59 (-1.96%)
After-hours: Oct 31, 2025, 7:44 PM EDT
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $13.82M in the quarter ending June 30, 2025, with 186.01% growth. This brings the company's revenue in the last twelve months to $199.89M, up 1,218.82% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$199.89M
Revenue Growth
+1,218.82%
P/S Ratio
8.63
Revenue / Employee
$1,561,664
Employees
128
Market Cap
1.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
STOK News
- 3 days ago - Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates - Business Wire
- 13 days ago - Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
- 17 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 24 days ago - Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - Business Wire
- 27 days ago - Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome - Business Wire
- 2 months ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Business Wire